Copyright ©The Author(s) 2018.
World J Gastroenterol. Jun 21, 2018; 24(23): 2457-2467
Published online Jun 21, 2018. doi: 10.3748/wjg.v24.i23.2457
Table 1 Phase III randomized controlled trials of vedolizumab in patients with ulcerative colitis and Crohn’s disease
Studyn (patients)Setting of trialTreatment armsClinical response (%)Clinical remission (%)CS-free remission (%)Mucosal healing (%)
GEMINI 1[10] 2013374Induction300 mg47.116.9-40.9
Maintenance300 mg 4 weekly-44.845.256.0
300 mg 8 weekly41.831.451.6
GEMINI 2[11] 2013368Induction300 mg31.414.5--
Maintenance300 mg 4 weekly45.536.428.8-
300 mg 8 weekly43.539.031.7
GEMINI 3[12] 2015315Induction300 mg-15.2--
Table 2 Real-world studies on vedolizumab in patients with inflammatory bowel disease, Crohn’s disease, or ulcerative colitis
Study author (country) yearsIBDCDUC
Amiot et al[15,16] (France), 2016-2017294173121
Eriksson et al[19] (Sweden), 2017246147991
Baumgart et al[17] (Germany), 201621297115
Dulai et al[23] (United States, multicentre), 2016212212-
Kopylov et al[20] (Israel), 2017204130741
Shelton et al[24] (United States, Boston), 2015172107651
Macaluso et al[22] (Italy, Sicily), 20181638479
Allegretti et al[26] (United States, Boston), 20171369640
Stallmach et al[18] (German Registry), 20161276760
Vivio et al[25] (United States, Saint Louis), 2016102 (51)23021
Samaan et al[21] (United Kingdom), 20175027231